Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vanderbilt university article on $YECO https://my.vanderbilt.edu/vinsenews/2020/10/vinse-has-established-a-new-partnership-with-ev-biologics/
$YECO EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University https://finance.yahoo.com/news/ev-biologics-perform-specialized-analysis-120000061.html?.tsrc=fin-srch
$YECO Yulong to List its Securitized Token on CryptoSX https://finance.yahoo.com/news/yulong-list-securitized-token-cryptosx-123500145.html?.tsrc=fin-srch
This is great financing without diluting shareholders
We are now updating and developing our new website to include the STO details and related public company information. Our STO financing will not require the issuance of any shares, thus minimizing dilution of existing shareholders. YECO will retain the majority ownership of the token, thus creating tremendous equity for shareholders.
The Company is preparing its updated accounting and intends to become fully reporting again before the end of Q4, 2020. YECO was previously a Nasdaq listed company and intends to up-list to OTCQB, then to a mainboard exchange again.
$YECO Yulong to Issue the Worlds’ First Biotech Securitized Token Offering https://finance.yahoo.com/news/yulong-issue-worlds-first-biotech-123000069.html?.tsrc=fin-srch
Here’s a website that explains about this stem cell research and why exosomes are best
https://www.exosomes.com/
I remember this from 2 years ago.
It runs fast.
Low float.
David
Yup ... nobody has been noticing till last couple days .... now people are starting to take not .... I don’t think this is close to done yet
Wow does this move fast on no volume.
News. Name change. New stock symbol.
Nice profits.
David.
New highs today... 3.21 .... great news hinting at what’s in store
https://www.otcmarkets.com/stock/YECO/news/Yulong-Intends-to-Develop-a-Cell-Biologics-Incubator-Lab?id=273370
watch this interview with EV Biologics CMO ... his is 3rd and requires password sanders
rechargebiomedical.com/inte...
the other interviews are eye openers as well
He is also president of a stem cell company as well as having his own orthopaedic surgery clinic
Very tight stock .... YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.
Very nice news .... just a hint as what’s coming at the end .... acquiring a stem cell company
$YECO Yulong Recruits Dr. Jason Sanders as CMO https://www.accesswire.com/603905/Yulong-Recruits-Dr-Jason-Sanders-as-CMO
OTCBB website SHOWS float is just a bit over 1mill
Amazing for a pink although .65 x .80 and pretty steady
Looks like OTCBB website is being updated
To EV Biogics Company info
Only 13.7 mill shares ... float is supposedly under 1million
Should expect a symbol change before to long As well.
Should move nicely on a little buying .... like yesterday
https://www.otcmarkets.com/stock/YECO/profile
Wow ... lots of volume today .... picked up a few more shares
Waiting for more updates on this new deal
New Company EV Biologics website
http://www.evbiologics.com/
Evolution of
Biologics Technology
EV Biologics Corporation – a biotechnology company dedicated to the science, study and commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics.
EVs are nano-scale, biological vessels containing bioactive protein and RNA molecules that form an intercellular communications network that governs the structure and function of the body. These natural biological signals directly influence the behavior of the cells that make up the tissues of the body. Certain types of EVs, such as those produced by neonatal stem cells, have demonstrated the innate capacity to suppress inflammation, modulate the immune system, promote cell survival, regenerate tissues, improve vascularity, reduce scarring and suppress cancer.
Enhancement of these intrinsic biological properties through bioengineering will enable EV Biologics to optimize therapeutics for many different disease states and traumatic injuries. The biological profile of circulating exosomes can also indicate pathologic states of the body, allowing the development of diagnostic modalities. The focus of EV Biologics is the development of EV technology for precision biopharmaceuticals, advanced diagnostics and regenerative cosmetics.
This has a huge spread ... but some shares have traded as high as .4699 today
Yulong Changes Name to EV Biologics
CHEYENNE, WY / ACCESSWIRE / August 6, 2020 / Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it has changed its name to EV Biologics, Inc. The Company is in the process of filing the necessary forms with FINRA and CUSIP to change the name and get a new trading symbol.
The Company moved its domicile from Cayman islands to Wyoming on April 12, 2019 and is currently in discussion to acquire a major USA based stem cell company as its platform business.
CEO Daniel Mckinney, said "we have embarked on a new business journey into the forefront of medical science. EV Biologics is currently recruiting the best of the best from the science and medical fields in the stem cell community to lead our research and product development. We will also retain experienced management from the pharma and biotech communities to lead our business."
About the Company
EV Biologics is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal "MSC" and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
Forward-Looking Statements
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
YECO has 9.91 million shares issued and outstanding with a float of 1,012,375 shares.
YECOF changed to YECO:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Sorry wrong board I was talking about yrcw
What’s the ticker these days? This company can’t still be trading?
Annnd what did the SEC do? Completely nothing against!
Some notice from activity- otcmarkets.com
Security Notes
Note = Delisted from Nasdaq on 7-11-2017
Note = Delisted from Nasdaq on 12-14-2018
Capital Change=shs decreased by 1 for 5 split. Ex-date=11/09/2017.
Symbol Change 07/11/2017 yecof Symbol change from YECO to YECOF
Symbol Change 10/02/2017 yecof Symbol change from YECOF to YECO
Symbol Change 12/14/2018 yecof Symbol change from YECO to YECOF
Of course, I can understand your misery, the Biggest Goal for now is: " How to explain somebody from Nevada the CHINESE STOLEN MONEY TRICKS, ITS REPEATING by THE SAME
SCENARIO ONLY, ONES,TWICE,THOUSAND TIMES, FOREVER!!!"
Ok, that was the most confusing message I’ve ever had the displeasure of reading.
Life is like a box of chocolates....Forest Gump. Wtf
Yuhoooo!!! NOT 3 YEARS, 3 MONTHS ONLY!!! HAHAHAHAHAH!!!!
THAT WAS MY TO DEATH SHORT FOR $250 millions. Thank You pumpers,
trust the YECOF, they will buy another art for them, where are your
money??? Lewi&Korsinski dislike to solve the People Stupidity First!!!
I had 100 “free” shares held after that last run... I guess I could take a $550 “loss” but I might just buy 900 shares when this death spiral looks like it’s slowing...
Agreed. I sold and took my loses.
Volume death spiral. Nothing left but some tremors all the way down. This thing is left for dead until a firm wants to pump it again.
Sure. But not going to pay to say I own a sliver of it by way of stock purchase and never touch it, while my investment stake goes down the toilet, as the directors use company dollars to pay for their extravagance as they tour the world talking about their jewel and painting all on shareholder’s dime.
That was a horrific sentence btw, but seriously, it’s an asset on the balance sheet with more to come by means of dilution. They will never sell the art at a premium and distribute a dividend of the profit to the shareholder. They will continue to take shareholder money and/or dilute by over gifting shares for art purchases. No realistic revenue stream to boost share price. They don’t report. They will not get relisted or uplisted to a better exchange. A stripper business model. Flashy, take your money and buy jewelry and art with it.
All my humble opinion of course. I lost some money here several weeks ago during the run-up, so I harbor some bitterness, but not without objectivity.
Do you like art?
Has possibilities imo. 3M market cap, but one art piece they own is worth $75M. I expect high volatility in the wake of the NASDAQ delisting.
You might want to look again. Company is a sham with a stripper business model.
Looks interesting here with this float
sub penny eventually
I wonder how low this will go? Looks like it's headed below $1.
Why was it delisted?
YECO changed to YECOF. Delisted from the Nasdaq to the OTC:
http://otce.finra.org/DLAdditions
ulong Eco-Materials Limited Announces NASDAQ Delisting
Email Print Friendly Share
December 13, 2018 17:31 ET | Source: Yulong Eco-Materials Limited
New York, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yulong Eco-Materials Limited (NASDAQ: YECO) (the “Company”), announced today that it has received notice from The Nasdaq Stock Market (“Nasdaq”) that Nasdaq will delist the ordinary shares of the Company. The Company’s ordinary shares will be suspended at the open of business on Friday, December 14, 2018. Nasdaq will file a Form 25 with the Securities and Exchange Commission when all internal appeal periods have run.
Following the delisting, the Company will continue as a publicly-traded entity. It is expected that the Company’s ordinary shares will be quoted on OTC Pink market electronic quotation service under the symbol “YECO.” The Company is exploring its options to have its ordinary shares quoted on other securities exchanges or over-the-counter markets.
About the Millennium Sapphire business
The Company plans to take the Millennium Sapphire on a tour of museums around the world, produce a television documentary, and include it the gemstone in a number of feature films. The Company will develop games around museum tours.
Contact:
Dennis Burns
Investor Relations
Tel 877-561-8101
dburns@nvestrain.com
* * $YECO Video Chart 12-13-18 * *
Link to Video - click here to watch the technical chart video
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
671
|
Created
|
10/08/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |